Interestingly, JAK/STAT signaling may also play a role in promoting the adeno-to-squamous transition observed in some LUADs following treatment with targeted therapies, including recently approved KRAS inhibitors.4,104,105,206 Encouragingly, recent activity combining the JAK/STAT inhibitor itacitinib with immune checkpoint blockade has shown promise in advanced LUAD.207 These findings suggest a broader role for JAK/STAT signaling in mediating lineage plasticity across different cancer types. This evidence concerns the gene SOAT1 and cancer.